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BRCA1 has been implicated in numerous DNA repair pathways that maintain genome integrity, however the function
responsible for its tumor suppressor activity in breast cancer remains obscure. To identify the most highly conserved of the
many BRCA1 functions, we screened the evolutionarily distant eukaryote Saccharomyces cerevisiae for mutants that
suppressed the G1 checkpoint arrest and lethality induced following heterologous BRCA1 expression. A genome-wide screen
in the diploid deletion collection combined with a screen of ionizing radiation sensitive gene deletions identified mutants that
permit growth in the presence of BRCA1. These genes delineate a metabolic mRNA pathway that temporally links transcription
elongation (SPT4, SPT5, CTK1, DEF1) to nucleopore-mediated mRNA export (ASM4, MLP1, MLP2, NUP2, NUP53, NUP120,
NUP133, NUP170, NUP188, POM34) and cytoplasmic mRNA decay at P-bodies (CCR4, DHH1). Strikingly, BRCA1 interacted with
the phosphorylated RNA polymerase II (RNAPII) carboxy terminal domain (P-CTD), phosphorylated in the pattern specified by
the CTDK-I kinase, to induce DEF1-dependent cleavage and accumulation of a RNAPII fragment containing the P-CTD.
Significantly, breast cancer associated BRCT domain defects in BRCA1 that suppressed P-CTD cleavage and lethality in yeast
also suppressed the physical interaction of BRCA1 with human SPT5 in breast epithelial cells, thus confirming SPT5 as a
relevant target of BRCA1 interaction. Furthermore, enhanced P-CTD cleavage was observed in both yeast and human breast
cells following UV-irradiation indicating a conserved eukaryotic damage response. Moreover, P-CTD cleavage in breast
epithelial cells was BRCA1-dependent since damage-induced P-CTD cleavage was only observed in the mutant BRCA1 cell line
HCC1937 following ectopic expression of wild type BRCA1. Finally, BRCA1, SPT5 and hyperphosphorylated RPB1 form a
complex that was rapidly degraded following MMS treatment in wild type but not BRCA1 mutant breast cells. These results
extend the mechanistic links between BRCA1 and transcriptional consequences in response to DNA damage and suggest an
important role for RNAPII P-CTD cleavage in BRCA1-mediated cancer suppression.
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INTRODUCTION
Inherited heterozygous BRCA1 and BRCA2 defects have been
associated with an enhanced risk of early onset breast cancer. These
tumor suppressor genes normally function to maintain genome
integrity by participating in the repair of DNA damage. Although
the repair-related functions of BRCA1 have been extensively
characterized (reviewed in [1]), identifying the underlying mecha-
nism responsible for the onset of breast cancer has remained elusive.
The BRCA1 protein functions in multiple pathways that maintain
genomic integrity through its impact on the repair of a variety of
genomic lesions including DNA double-strand breaks (DSBs).
BRCA1 participates in recombinational repair of DSBs, non-
homologous end-joining of DSBs, checkpoint arrest, transcriptional
regulatory mechanisms and chromatin remodeling as well as
centrosome duplication [1] [2]. Moreover, the BRCA1 protein has
been found to physically interact with numerous other proteins in
distinct, multi-component DNA repair complexes [3] [4] [5].
Although BRCA1 seems to be a central DNA repair component
due to its many physical interactions in repair-related processes, the
tumor suppressor activity is largely confined to breast and ovarian
epithelia [1]. To resolve this enigma, BRCA1 has been suggested to
interact with a subset of tissue specific, non-redundant cofactors in a
single key pathway to mediate its tumor suppressive effects.
As an alternative approach for studying this important repair
protein, we have utilized the yeast Saccharomyces cerevisiae, which has
served as the fundamental model organism for the identification of
the genetic controls associated with DNA repair and checkpoint
functions that are conserved in most eukaryotes [6]. Yeast is an
excellent model organism for elucidating BRCA1 function since
heterologous expression of BRCA1 causes slow growth and lethality
in both haploid [7] and diploid [8] wild type (WT) yeast. Mutations
within the BRCT domain of BRCA1 that are associated with
familial breast cancer, but not polymorphisms without disease
association, suppress this slow growth phenotype [7].
In order to identify a key pathway that may underlie the
tumorigenic potential of BRCA1 in breast cancer, we took advantage
of the evolutionary distance between humans and yeast. In effect, we
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that, through severe functional constraints, have maintained the
ability to interact with BRCA1 over a vast evolutionary distance.
Other successful examples of this approach include the identification
of relevant conserved genetic and biochemical networks that interact
with mutantHuntington protein as well as alpha-synuclein, which has
been implicated in the pathology of Parkinson’s disease [9; 10]. Since
interaction of BRCA1 with such conserved proteins may account for
lethality in WT yeast, we screened for nonessential gene deletions in
the yeast diploid deletion collection that suppressed BRCA1-induced
lethality. Previously, we described that deletions of the G1 checkpoint
adaptation genes CCR4 or DHH1 that also mediate radiation
resistance, suppressed BRCA1-induced lethality [8].
In this report we screened both ionizing radiation (IR) sensitive
mutants and an unselected pool of yeast deletion mutants to identify
additional suppressors of GAL-induced BRCA1 lethality. Many of
these suppressors are functionally and temporally linked in mRNA
metabolic processes that include transcriptional elongation, mRNA
export and decay. Focusing on the process of elongation, we
demonstrate in human cell extracts that BRCA1 can be co-
immunoprecipitated with the human ortholog of Spt5p and
hyperphosphorylated RNAPII. We show that BRCA1 interacts
with the Ct erminal domain (CTD) of RNA polymerase II (RNAPII)
when the CTD is phosphorylated in a pattern specified by the
CTDK-Ikinase(CTK),tomediatephospho-CTD(P-CTD)cleavage.
This P-CTD cleavage is not induced by cancer-associated mutations
in the BRCT domain (C-terminal domain of BRCA1) and is
suppressed by genomic deletion of the RNAPII degradation factor
DEF1 and CTK1, the CTD kinase that results in phosphorylation of
serine 2 and serine 5. We further show that UV-irradiation results in
a proteasome dependent accumulation of the P-CTD cleavage
product inyeastand human breast cancer cells wildtype for BRCA1
but not in a BRCA1 mutant cell line. Ectopic expression of the wild
type BRCA1 protein in this mutant line restores damage dependent
P-CTD cleavage indicating a direct mechanistic link between
BRCA1 and this newly discovered RNAPII processing event. From
this and other supportive data, we propose a model in which
BRCA1-induced RNAPII P-CTD cleavage and degradation is a key
component of a highly conserved, checkpoint/surveillance pathway
that detects DNA damage within actively transcribing genes.
RESULTS
A genome-wide screen for suppressors of BRCA1-
induced lethality in yeast identifies genes required
for mRNA elongation, export and decay
Although a BRCA1 ortholog is not found in the yeast S. cerevisiae,
expression of BRCA1 in yeast results in slow growth and lethality.
We reasoned that an interaction of BRCA1 with a conserved yeast
protein(s) interferes with a basic cellular function essential for yeast
survival and that these proteins would be intimately involved in the
maintenance of genomic integrity. By screening for rapid growth
on GAL-URA (GAL) medium immediately following transforma-
tion of the BRCA1 expression plasmid into a pool of genetically
tagged deletion strains, we initially identified a total of 48 mutant
strains that suppressed BRCA1 lethality. Typically upon screen-
ing, the WT strain containing the BRCA1 plasmid failed to grow
on GAL beyond the first or second dilution (Fig. 1A,B) and the
relative colony forming survival fraction was 0.09860.089 (i.e.,
90.2% of WT cells fail to survive BRCA1 induction; n=3361 SE;
Fig. 1C). Of the 48 deletion strains that were initially identified to
suppress BRCA1, 20 (42%) were subsequently confirmed to
suppress lethality greater than 2 fold over WT in an independently
transformed yeast deletion isolate (Table S1).
As a secondary screen, we also examined the 203 deletion strains
that we previously found to be radiation sensitive [11] [12]. Thirteen
of these were found to suppress BRCA1 lethality (Table S1). These
included dhh1D and ccr4D, previously characterized as suppressors
[8], def1D which is involved in RNAPII degradation following DNA
damage[13],a number of nuclearpore proteins required for mRNA
transport, as well as two open reading frames (ORFs; yml009c-a and
yml009w-b) that overlap the 39 end of SPT5 to truncate the protein.
We collectively identified mutants with defects in highly conserved
cellular processes that primarily affect mRNA metabolism. Specif-
ically, these processes include transcription elongation (DEF1, SPT4,
SPT5, SUB1), mRNA export (MLP2, ASM4, NUP2, NUP120,
NUP133, NUP170, NUP188, POM34; Fig. 1B) and mRNA decay
at cytoplasmic processing bodies (DHH1, CCR4). Using these
screening approaches, we identified a total of 36 deletion strains
that suppressed BRCA1 lethality (Table S1).
Extensive genome-wide proteomic and genetic interaction
networks have been characterized in yeast. We utilized these
interaction networks (listed at SGD) to determine whether genes or
gene products that genetically or physically interact with experi-
mentally identified suppressors of BRCA1 (Table S1) could identify
additional deletion mutations that suppress BRCA1 lethality. Using
known network interactions, we identified a further 9 deletions
including mlp1D and nup53D as suppressors of BRCA1. Moreover,
geneticinteractionsofBRCA1withRNAPIIelongationcomponents
predicted ctk1D and srb10D (ssn3D) as suppressors of BRCA1-
induced lethalitydue to their impacton RNAPII C-terminal domain
(CTD) phosphorylation (described below). Thus a total of 45
suppressors of BRCA1 lethality were identified (Table S1).
Suppression of lethality is not due to reduced
BRCA1 expression, nuclear exclusion or second site
suppressors
Since suppressors of BRCA1 lethality could have an impact upon
mRNA expression and export or nuclear import of the BRCA1
protein, we analyzed representative strains for BRCA1 expression
and subcellular localization. Following a standard whole cell
extraction protocol using ice-cold NP40 buffer, BRCA1 was
extensively degraded even in the presence of protease inhibitors
(data not shown). To alleviate this problemwe adopted an extraction
protocol in 95% ethanol that rapidly fixes the cells and greatly
reduced BRCA1 degradation (see Materials and Methods). GAL-
induced expression of BRCA1 protein was unaffected by deletion of
the major transcriptional regulators that suppress lethality when
compared to WT (Fig. 1D). Furthermore, intranuclear localization
of GAL-induced BRCA1 was unaffected in suppressor mutants that
regulate transcription (spt4D) or nuclear pore functions (nup170D)a s
determined by immunofluorescent detection (IF, Fig. 1E). Further,
we ‘‘covered’’ three of the major suppressor deletion strains by
expressing the SPT4, CTK1 and DEF1 genes. In each case, BRCA1
lethality was restored on GAL indicating that second site mutations
were not responsible for the suppressor phenotype (Fig. 1F). Thus
suppression of BRCA1 lethality appears to result from the identified
gene deletions and absence of the corresponding gene products that
functionally mediate the lethal BRCA1 response.
Recombination and TCR repair are dispensable for
BRCA1-induced lethality
In human cells, BRCA1 has been shown to interact with
components of the recombinational repair apparatus (Rad51p)
as well as components of the non-homologous end-joining
pathway which are all highly conserved in yeast and required
BRCA1 Mediated RNAPII Cleavage
PLoS ONE | www.plosone.org 2 January 2008 | Issue 1 | e1448Figure 1. Identification and characterization of genetic suppressors of BRCA1-induced lethality in yeast. (A) Suppression of BRCA1-induced
lethality following transformation of isogenic deletion strains with BRCA1 plasmid. BRCA1 suppressor strains were initially identified by sequencing
rapid growing strains arising on GAL-URA plates following transformation of the diploid deletion strain pool with the GAL::BRCA1 expression plasmid.
Putative BRCA1 suppressor strains identified from the pool were selected from the arrayed deletion strain library and transformed with the BRCA1
expression plasmid, grown to stationary phase in GLU and 2 ul aliquots were replica spotted onto GLU and GAL plates from serial 5-fold dilutions in
water (arrows indicate direction of decreasing cell concentration). Typical results are depicted for seven strains. Five deletion strains (apt1D, nst1D,
oca1D, ygr039WD and ylr412WD) failed to suppress BRCA1 lethality and were omitted from further study. Two deletion strains, bbc1D and ygr064WD
(which deletes the N terminus of SPT4) were confirmed to suppress BRCA1-induced lethality. (B) Deletion strains defective in mRNA export suppress
BRCA1-induced lethality. Deletions of the nuclear pore associated genes NUP2, POM34 and MLP2 (from deletion pool) and deletions of the IR
resistance genes NUP120, NUP170, NUP188 as well as NUP133 (not shown, Table S1) suppress BRCA1 lethality. Relative plating efficiencies for colony
formation on GAL vs GLU (GAL/GLU) are from Table S1. With the exception of nup84D, all IR sensitive nuclear pore defective strains significantly
suppressed BRCA1-induced lethality. (C) Deletion of the transcriptional elongation genes SPT4 or CTK1 completely suppress BRCA1-induced lethality.
Reduced colony forming ability on GAL (Galactose) vs GLU (Glucose) plates is completely suppressed by deletion of SPT4 or CTK1 when compared to
WT strains containing the BRCA1 plasmid. Plates depicted are following 3 (WT and spt4D strains) and 4 days (ctk1D) incubation at 30uC. (D)
Suppressor strains defective in transcription elongation express BRCA1. WT, spt4D, def1D and ctk1D strains containing the BRCA1 expression plasmid
were induced in liquid GAL for the indicated times (hrs). Western blot has been probed with anti-BRCA1 antibody MS110. Full-length BRCA1 has an
apparent MW of 220–250 kDa or larger (arrow). (E) Nuclear exclusion of BRCA1 is not responsible for suppression of BRCA1-induced lethality. In situ
immunofluorescence of BRCA1 was determined in uninduced yeast cells (GLU) or induced for BRCA1 expression for 6 hours (GAL). Hoechst staining
was used to position the nucleus. No partitioning defects were observed for BRCA1 in other nuclear pore mutants (nup2D, nup120D, nup133D,
nup188D, pom34D or mlp2D; data not shown) that suppressed BRCA1 lethality. In all cells examined, BRCA1 was localized to both the nucleus and
cytoplasm. Bar is 10 um. (F) Suppression of BRCA1-induced lethality is not due to second site suppressors. Diploid deletion strains (spt4D, ctk1D and
def1D) containing the GAL::BRCA1 expression plasmid were ‘‘covered’’ with the corresponding gene expressed from a second selectable plasmid and
assayed for the reinstatement of BRCA1 lethality by determining the relative plating efficiencies of colony forming ability on GAL vs GLU with
selection for both plasmids. WT+BRCA1 (-HIS) is the relative survival of colony forming ability for the WT strain containing the GAL::BRCA1-HIS3
expression plasmid on GAL-HIS vs GLU-HIS medium. Error bars are +/2 1 SD about the mean and each bar represents 3-6 experiments.
doi:10.1371/journal.pone.0001448.g001
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strains individually deleted for members of the RAD52 epistasis
group to determine if lethality was suppressed following GAL
induced expression of BRCA1. Only some repair defective strains
(i.e. rad50D, rad51D, rad52D, rad55D and xrs2D) demonstrated a
modest suppression of BRCA1-induced lethality (Table S1). No
suppression of BRCA1-induced lethality was observed for rad54D,
rad57D or rdh54D strains (data not shown). Since DEF1 [16] and
SPT4 [17] have been linked to transcription-coupled repair (TCR),
we also examined a number of strains (rad7D, rad16D, rad23D,
rad26D, rad28D, met18D, rpb4D and rpb9D) deleted for genes that
have been implicated in TCR to determine if any were required
for BRCA1-induced lethality. Following deletion of components of
the yeast TCR apparatus, little (RAD16, MET18, RPB4; Table S1)
or no (RAD7, RAD23, RAD26, RAD28, RPB9; data not shown)
suppression of BRCA1-induced lethality was observed. These
results suggest that recombination, non-homologous end-joining
and TCR-mediated repair pathways are not responsible for the
majority of the BRCA1-induced lethality in yeast.
The DSIF complex is required for BRCA1-induced cell
cycle arrest and the maintenance of genomic
integrity following DNA damage
Spt4p and Spt5p physically interact in the DSIF (5,6-dichloro-1-
beta-D-ribofuranosylbenzimidazolesensitivityinducingfactor)com-
plex with RNAPII to affect transcription elongation in both yeast
[18] and human cells [19]. Although SPT5 is an essential gene in
yeast, two overlapping ORFs from the deletion collection truncate
the carboxy terminal end of SPT5 yet retain viability (yml009w-bD,
yml009c-aD, Table S1). Furthermore, ygr064wD deletes the N
terminus of Spt4p. These deletion strains all suppressed BRCA1
lethality (Fig. 2A) and similar to isogenic dhh1D and ccr4D strains,
which have a checkpoint adaptation function [8] [12], deletion of
SPT4 suppressed the prolonged G1 arrest induced by expression of
BRCA1 (Fig. 2B). DSIF defective yeast strains also exhibit IR
sensitivity (Fig. 2C) previously described for the SPT5 truncations
[11]. Furthermore DSIF defects resulted in enhanced sensitivity to
the S phase specific damaging agents HU and MMS (Fig. 2D,E).
Moreover, the spt4D allele resulted in enhanced chromosome
instability, both spontaneously and following MMS exposure, when
transferred into a strain that detects enhanced loss of a stable YAC
(yeast artificial chromosome; Fig. 2E). These data indicate a shared
role for the DSIF complex in DNA damage tolerance, maintenance
of genomic stability and suppression of BRCA1-induced lethality in
yeast. Taken together, these results suggest that BRCA1 subverts a
conserved DNA damage response pathway in yeast in which DSIF
plays a critical role.
Other BRCA1-interactive targets mediate resistance
to DNA damaging agents
Many of the newly identified suppressors of BRCA1-induced
lethality have not been previously associated with DNA damage
sensitivity. Testing these strains, we found that most of the
suppressor strains (11/17) demonstrated enhanced IR sensitivity
(,5–10 fold) when compared to WT. Further, all of these strains
were hypersensitive to the toxin zymocin (Fig. 2F) that arrests cells
in the G1 phase of the cell cycle and affects a number of RNA
metabolic processes including transcription elongation [12]. These
results lend additional support for the biological relevance of this
screen since we identified proteins involved in the maintenance of
genomic integrity following DNA damage, a BRCA1-dependent
process in human cells.
BRCA1-induced lethality in yeast is mediated by
genome instability and plasmid loss
Loss of BRCA1 function in human cells results ingenome instability.
We therefore investigated whether expression of BRCA1 in yeast
was also genome-destabilizing and could account for some or all of
the lethality observed in yeast. We first examined whether lethality
was dependent on plasmid selection following expression of BRCA1
(Fig. 3A). In order to determine the kinetics of BRCA1-induced
plasmid loss and subsequent lethality, we performed a ‘‘pullback’’
experiment in which WT cells containing the BRCA1 plasmid or
empty vectorwere plated withinGAL-URA orGAL+URA medium
to induce BRCA1 expression. At increasing time intervals, we
overlaid the GAL plates with either GLU-URA or GLU+URA
medium to repress BRCA1 expression. When plasmid selection
(-URA) was maintained throughout the experiment so that only
plasmid retaining cells would survive, a rapid time dependent
decrease in survival was observed. Following plating under non-
selective conditions (+URA) survival was still significantly reduced as
compared to WT cells containing empty vector, however survival
was increased as compared to that under selective conditions
indicating that loss of the plasmid selectable marker comprises only
part of the observed BRCA1-induced lethality (Fig. 3A). We also
directly analyzed plasmid loss in both WT and spt4D by Southern
blotting (Fig. 3B). Supporting the growth result, dramatic plasmid
loss is evident in WT. In contrast, the efficient suppressor of lethality,
spt4D retained plasmid throughout the experiment. We also
demonstrated plasmid retention in spt4D using a similar pullback
approach following BRCA1 expression in liquid medium (Fig. 3C).
Thus plasmidand chromosomal instability appears to play a key role
in BRCA1-induced lethality in yeast.
BRCA1-induced lethality in yeast requires the BRCT
domain
In yeast, slow growth following expression of BRCA1 [7] was shown
to be associated with the BRCT domain [20]. We separately
introduced two breast cancer associated BRCT mutations into the
yeast BRCA1 expression plasmid. In one construct, we introduced a
single nucleotide change that resulted in a BRCT amino acid
substitution (I1766S). For the second mutation, we introduced a
prematurestopcodon thattruncated the BRCA1 proteinbydeleting
the last 10 C-terminal amino acids. Following GAL induction, both
mutant proteins were expressed in amounts similar to that observed
for the full-length WT BRCA1. Neither of these mutant BRCA1
proteins reduced yeast survival following expression (Fig. 3D; data
not shown). To extend this observation, we cloned the final 333
amino acids of BRCA1 containing the tandem BRCT domains into
the yeast high copy expression plasmid pDEST52. Similar to full-
length BRCA1, expression of the BRCT construct in WT yeast
resulted in significant but slightly reduced lethality (relative survival
fraction=0.2160.06; 61 SE). Thus, the majority of the lethality
observed in yeast following expression of full-length BRCA1 appears
to be mediated through the BRCT domain.
CTDK-I (CTK1 kinase) is required for BRCA1-induced
lethality in yeast
A critical and unique feature of elongating RNAPII is its hyperpho-
sphorylated and highly conserved CTD domain. The identity of
several suppressor strains as well as the ability of BRCA1 to
modulate RNAPII CTD phosphorylation [21] suggested a connec-
tion between BRCA1 and transcription elongation by RNAPII. We
therefore tested whether deleting genes in subunits of three different
CTD kinases could suppress BRCA1 lethality. We found that
BRCA1 Mediated RNAPII Cleavage
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suppression of BRCA1 lethality. Remarkably, deleting CTK1
completely suppressed BRCA1 lethality (Table S1, Fig. 1C). This
result argues that BRCA1 lethality requires CTK1-dependent
phosphorylation of the RNAPII CTD, and suggests that the
molecular mechanism of BRCA1 lethality requires the pattern of
CTD phosphorylation specified by CTDK-I [22] [23].
BRCA1 genetically interacts with the CTD of RNAPII
Since the DSIF complex and the Ctk1p suppressor kinase interact
with the elongating form of RNAPII and the regulatory CTD
domain of Rpb1p plays a key role in transcription elongation [24],
we investigated whether overexpression of the yeast RNAPII CTD
could influence BRCA1 lethality. To do this we constructed a
C-terminal fusion of the yeast RNAPII CTD to b-galactosidase
Figure 2. BRCA1 suppressor strains are sensitive to DNA damaging agents. (A) DSIF defective strains suppress BRCA1-induced lethality. Deletion of the
ygr064WD ORF deletes the N terminus of SPT4. Full-length deletion of SPT4 also completely suppressed BRCA1 lethality. Spt4p physically interacts with
Spt5pintheDSIFcomplextoconfertranscriptionelongationfunctions.SPT5is anessentialgene,howevertherelativesurvivaloftwostrains(yml009W-bD
and yml009c-aD) containing non-lethal C terminal truncations of SPT5 was enhanced when compared to WT following BRCA1 expression. Relative colony
forming ability for these strains on GAL vs GLU (GAL/GLU) has been indicated. (B) Deletion of SPT4 suppresses prolonged G1 arrest following BRCA1
expression in yeast. Individual unbudded (G1) cells were positioned using a micromanipulator into 465 cell grid patterns on GLU-URA and GAL-URA
plates. None of the WT cells expressing BRCA1 (on GAL) were able to progress beyond the single cell (G1) stage of the cell cycle by 24 hours. However,
deletionof SPT4allowed most of the cells (13/20) to progressinto microcolonies following BRCA1 expression. When BRCA1 was repressed (on GLU), most
of the WT and the spt4D cells progressed beyond the G1 stage of the cell cycle to form microcolonies. (C) DSIF defective yeast strains are sensitive to c-
irradiation. WT, spt4D and spt5 mutant (yml009w-bD) strains were grown to stationary phase and exposed to c-irradiationas previously described [12]. WT
survival data was pooled with previous data (n=10 experiments) to generate the c-ray WT survival curve depicted above. Survival fractions for the spt4D
and spt5 strains are averaged from 3-4 experiments. Previously published survival data for the ccr4D strain [12] has been included for comparison. Error
bars are +/2 1 SE about the mean. (D) Diploid spt4D strains are sensitive to the S phase specific DNA damaging agents HU and MMS. WT, spt4D,s p t 5
truncated (yml009w-bD; yml009c-aD)a n dccr4D strains were exposed as described in Methods. Arrows indicate the direction of decreasing cell
concentrations. The ccr4D strain has been included as a positive control. (E) SPT4 maintains chromosome stability following DNA damage. The WT
(YPH656) and isogenic spt4D YPH656 derived strain contain a stable YAC that carries the SUP11 gene that allows read through of the ochre mutation
withinade2-101.StrainsthatretaintheYACremainwhitewhilelossoftheYACresultsinaredcolony.StrainsweregrownanddilutedasdescribedinPanel
D. Two independent spt4D isolates demonstrate MMS hypersensitivity and enhanced MMS-induced chromosome loss as indicated by numerous (n=10)
red Ade- colonies (arrows) when compared to the WT parental YPH656 strain (no red colonies). Spontaneous YAC loss was observed in untreated spt4D
strains. (F) BRCA1 suppressor strains are sensitive to c-irradiation and hypersensitive to zymocin. Strains were grown and diluted as described in Panel D.
Diluted cells were replica spotted onto YPD and either left unirradiated (0 Dose), exposed to 80 krads of c-irradiationor plated to YPD containing zymocin
toxin secreted from K. lactis as previously described [12].
doi:10.1371/journal.pone.0001448.g002
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constructs were inserted into a selectable GAL1 expression vector
and following expression of these fusion protein constructs, the b-
galactosidase-CTD fusion was found predominantly in the
cytoplasm (cyto-CTD; no NLS) or in the nucleus (nuc-CTD; with
NLS) as determined by in situ IF (data not shown). In WT yeast
that concomitantly express BRCA1 from a second selectable
plasmid, expression of the cyto-CTD significantly suppressed
BRCA1-induced lethality whereas expression of the nuc-CTD
significantly augmented the lethality of BRCA1 (Fig. 4A). Part of
this augmented BRCA1-induced lethality appears to be directed
towards enhanced nuc-CTD plasmid instability as addition of
Figure 3. BRCA1-induced lethality involves plasmid loss and requires a functional BRCA1-BRCT domain. (A) ‘‘Pullback’’ of WT yeast containing
either the BRCA1 expression plasmid or empty vector control. To induce BRCA1, dilutions of plasmid bearing cells were plated into cooled liquid GAL
agar containing medium with (+URA) or without (-URA) uracil selection for the plasmid marker (URA3) as previously described [54]. At the indicated
times, BRCA1 expression was repressed by overlaying with GLU+URA or GLU-URA agar. For some data points, error bars (+/2 1 SD) are contained
within the symbol. Enhanced lethality under selective conditions indicates plasmid loss is a significant component of BRCA1-induced lethality. (B)
Deletion of SPT4 suppresses the physical loss of the BRCA1 expression plasmid. Stationary cultures of WT and spt4D strains containing the BRCA1
plasmid were ‘‘split’’ into twice the volume of GAL or GLU to express or repress BRCA1 respectively. Expression of BRCA1 in WT cells (in GAL) resulted
in a time dependent increase in plasmid loss as determined by Southern analysis. Cells deleted for SPT4 retain the BRCA1 plasmid following BRCA1
expression. When BRCA1 was repressed, plasmid was physically retained in both WT and spt4D strains. (C) SPT4 deletion suppresses plasmid loss
following BRCA1 expression. The viability of cells from the experiment described in Panel B was determined by plating aliquots at the indicated times
onto YPD agar medium and genetically determining plasmid loss by replica plating the resulting colonies onto GLU-URA plates to detect the
presence or absence of the plasmid URA3 marker (URA+). The relative survival of colony forming ability following repression (in GLU; left panel, two
experiments) or induction of BRCA1 (in GAL; right panel, four experiments) in liquid media is shown. A significant loss of the plasmid marker can be
observed in the WT but not in the spt4D strain following BRCA1 expression. No significant loss of the BRCA1 plasmid can be seen for either strain
when the cells were grown in GLU. (D) Breast cancer associated mutations within the BRCT domain of BRCA1 suppress lethality in yeast. A single base
pair was mutated within the BRCA1 expression plasmid (I1766S). The relative survival of colony forming ability on GAL vs GLU (GAL/GLU survival, four
experiments) was determined as described for Fig. 1B. Complete suppression of BRCA1-induced lethality in yeast was also observed following
deletion of the C-terminal 10 amino acids of BRCA1 that also disrupts BRCT domain function (data not shown).
doi:10.1371/journal.pone.0001448.g003
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PLoS ONE | www.plosone.org 6 January 2008 | Issue 1 | e1448Figure 4. BRCA1 interacts with the phosphorylated RNAPII CTD to induce cleavage and proteasome-mediated degradation. (A) BRCA1 genetically
interacts with the RNAPII CTD in WT yeast. WT yeast cells were transformed with plasmids that express the RNAPII CTD in the nucleus (nuc-polII CTD) or
cytoplasm (cyto-polII CTD) due to the presence or absence of a NLS signal sequence. A second selectable (HIS3) GAL::BRCA1 expression vector was
subsequently established in these strains by transformation. Relative plating efficiencies on GAL vs GLU was determined as described in Fig. 1B with
plasmid selection. Co-expression of the BRCA1 and the cyto-CTD construct significantly (*) suppressed BRCA1-induced lethality, whereas co-expression of
BRCA1 and the nuc-CTD construct significantly (*) augmented lethality. The relative survival fraction for cells containing both the BRCA1 and nuc-CTD
plasmids was less than (,) 0.08 since no colonies appeared on the GAL-HIS-URA plates. This augmented lethality could be partially ‘‘relieved’’ by plating
cells to non-selective medium where retention of the nuc-CTD construct was not required for viability (in medium containing uracil; +URA). This indicated
that nuc-CTDplasmid loss occurredintransfollowingBRCA1expression.Error barsaretheaverageof4-6 experiments(+/21S D ) .( B )B R C A 1e x p r e s s i o ni n
WT yeast induces cleavage ofthe RNAPII CTD. Following BRCA1 expressionin WT cells, Western blots were probed withanti-2,5P CTDantibody (anti-2,5P,
upper panel), stripped and re-probed with anti-BRCA1 antibody (lower panel). The positions of the intact phosphorylated RNAPII (IIo) and a novel BRCA1-
induced 50 kDa phospho-CTD (P-CTD) fragment have been indicated. (C) WT yeast that express BRCA1 with a BRCT domain defect fail to induce P-CTD
cleavage. WT cells containing BRCA1, BRCT mutated (I1766S) or empty plasmid expression vectors were induced for BRCA1 expression in GAL and
extracted at the times indicated. Western blots utilized anti-2,5P CTD (upper panel) and anti-BRCA1 (middle panel) antibodies as probes. Anti-Act1p
antibody (bottom panel) served as a loading control. P-CTD cleavage in cells containing the empty vector was identical to that seen for the BRCT mutant
expression plasmid (data not shown). (D) Deletion of DEF1 inhibits BRCA1-induced P-CTD cleavage. WT and def1D strains containing the BRCA1 plasmid
were induced for BRCA1 expression and extracted at the indicated times. Anti-2,5P CTD (upper panel) and anti-BRCA1 (middle panel) antibodies were
utilized as Western blot probes. Pgk1p served as a loading control unaffected by the switch from GLU to GAL (bottom panel). The P-CTD fragment is
greatly diminished in the def1D strain when compared to an equivalently loaded WT induced for BRCA1 expression. (E) Deletion of CTK1 inhibits BRCA1-
induced P-CTD cleavage. WT and ctk1D strains containing the BRCA1 plasmid were induced for BRCA1 expression and extracted at the indicated times.
Cells wereextracted, proteinsseparated andWestern blotted as described inC above. TheP-CTD fragmentisundetectable inthe ctk1D strain usingeither
anti-2,5P or H14 anti-5 P antibody (data not shown). (F) MG132 inhibits degradation of the BRCA1-induced P-CTD fragment in yeast. Deletion of ERG6
facilitates uptake of the proteasome inhibitor MG132 in yeast. We therefore established the BRCA1 expression plasmid within the erg6D strain and
induced BRCA1 expression in the absence (left panels) and presence of MG132 (right panels). Persistence of the P-CTD fragment is enhanced by MG132
treatment indicating that the P-CTD fragment is targeted for proteasome-mediated degradation.
doi:10.1371/journal.pone.0001448.g004
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plasmids) to the GAL plates decreased the lethal effects of co-
expressing BRCA1 and the RNAP II CTD in the nucleus. Thus
RNAPII CTD co-expression significantly altered the degree of
BRCA1 lethality and indicated a genetic interaction between
BRCA1 and the expressed RNAPII CTD.
BRCA1 expression in yeast results in cleavage of the
RNA polymerase II P-CTD
Given the genetic connections between BRCA1 lethality and the
Rpb1p CTD, we examined the status of RNAPII following
BRCA1 expression in yeast, employing a polyclonal antibody
raised and purified against a synthetic CTD repeat peptide
phosphorylated on every Ser2 and Ser5 residue (anti-2,5P), the
pattern of phosphorylation preferentially generated by CTDK-I
(CTK1 kinase, [22] [25]). Unexpectedly, the predominant band
observed in Western blots of extracts from cells expressing BRCA1
was not the intact, hyperphosphorylated Rpb1p subunit (IIo), but
a band with an electrophoretic mobility of 50 kDa (Fig. 4B). This
50 kDa species appears to represent the P-CTD, cleaved from the
rest of the Rpb1p subunit (the N-terminal fragment would not be
detected by the anti-2,5P antibody). Its mobility is what might be
expected for a segment of Rpb1p containing the entire hyperpho-
sphorylated CTD plus an additional ,100 amino acids N-
terminal to the CTD. The appearance of this P-CTD fragment
depends on the expression of WT BRCA1 (Fig. 4B) since it was
observed in only very limited amount after expression of the two
disease associated BRCA1 mutants or after galactose induction of
cells containing empty vector (Fig. 4C; data not shown). BRCA1-
induced accumulation of the P-CTD fragment also was found to
be dependent on the DEF1 gene (Fig. 4D) whose product has been
implicated in ubiquitin-mediated proteasomal degradation of
RNAPII stalled following UV damage [13]. Furthermore,
BRCA1-induced accumulation of the P-CTD fragment was
similarly reduced in the ctk1D strain even though BRCA1 was
expressed at levels comparable to that observed in the isogenic
WT strain (Fig. 4E). BRCA1-induced accumulation of the P-CTD
fragment was enhanced by concomitant treatment with the
proteasome inhibitor MG132 in the permeable erg6D strain
suggesting that the P-CTD was subject to proteasome-mediated
degradation following cleavage (Fig. 4F). To confirm the identity
of the 50 kDa species, we were able to detect this band after
BRCA1 expression in strains that express an Rpb1p allele with a
C-terminal His10 tag or a reduced number of heptapeptide repeat
units in the CTD (Figure S1). Taken together, these results
indicate that expression of BRCA1 with an intact BRCT domain
in yeast leads to the appearance of a novel P-CTD fragment,
cleaved from a form of RNAPII whose phosphorylation state is
dependent on CTDK-I. Subsequent stability of this fragment is
influenced by the proteasome system.
BRCA1 interacts with the DSIF complex in yeast and
human cells
Suppression of BRCA1-induced lethality in spt4D and spt5 yeast
strains suggests that the DSIF complex may mediate interaction of
BRCA1 with RNAPII. Therefore, we tested whether components
of the DSIF complex physically interact with BRCA1 in yeast and
human cells. Following expression of a V5 tagged Spt4p in yeast
co-expressing BRCA1, we were able to co-IP BRCA1 and Spt4p
(Fig. 5A). As our genetic screen in yeast was intended to identify
novel BRCA1 interactive targets in mammalian cells, we turned
our attention to a more physiologically relevant system. Using
lysates from the MCF7 breast cancer cell line that harbors wild
type BRCA1, we detected an interaction between endogenous
SPT5 and BRCA1 by co-IP analysis. This interaction was present
both in unirradiated cells (Fig. 5B,C) and in cells following 20 J/
m
2 of UV-irradiation (Fig. 5B). In HCC1937 cells harboring a
hemizygous BRCA1 mutation (5382insC resulting in mistransla-
tion starting at codon 1755 and premature termination at 1829),
we found no detectable interaction between these two proteins,
with or without DNA damage suggesting that the BRCA1 C-
terminal domain is required. In MCF7 cells the interaction was
detectable in both directions using either SPT5 or BRCA1 as a
capture protein (Fig. 5C, right half). Finally, interactions between
SPT5, BRCA1 and the phosphorylated full-length form of RPB1
(IIo) were also detectable in unirradiated MCF7 cell extracts
(Fig. 5C, left half).
MMS treatment induces rapid degradation of
BRCA1, SPT5 and RPB1
BRCA1 appears to have ubiquitin ligase activity, with phosphory-
lated RPB1 acting as a substrate in a DNA damage responsive
manner [26] [27] . Since SPT5 appears to be associated with both
BRCA1 andthe RNA polymerase, we asked whether its degradation
was influenced by BRCA1 or DNA damage. Treatment of MCF7
and HCC1937 cells with the radiomimetic alkylating agent MMS
for 2h induced a dramatic dose dependent decrease in steady-state
SPT5 levels in the BRCA1 wild type MCF7 cells but not the mutant
HCC1937 line (Fig. 5D). Loss of BRCA1 and RPB1 was also much
more dramatic in MCF7 cells providing further evidence for a
functional link between these proteins. Proteasome inhibition only
partially prevented the damage-induced loss of all three proteins in
MCF7 cells (data not shown). Dependence of damage-induced
degradation of BRCA1, SPT5 and RPB1 on a functional BRCA1-
BRCT domain suggests that this BRCA1-mediated degradation
pathway may be critical for the suppression of tumorigenesis.
Moreover, the BRCA1-mediated co-degradative loss of the
abundant SPT5 protein along with RNA polymerase II suggests
that the DSIF complex may have a key role in maintaining RNAPII
stability prior to DNA damage.
P-CTD cleavage is induced following DNA damage in
yeast and human cells
Since BRCA1 may subvert a conserved transcription associated
damage pathway in yeast to exert its lethal effects, we examined if
UV-irradiation, an efficient block to transcriptional elongation,
could also induce P-CTD cleavage in yeast. Following a moderate
dose of UV irradiation (120 J/m
2), a transient 50 kDa P-CTD
fragment was detected between 4 and 5 hours post irradiation
(Fig. 6A).
Although the repeated RNAPII CTD sequence of yeast and
human cells is highly conserved, the human CTD is approximately
twice the length of the yeast CTD. Consistent with this larger size,
following UV-irradiation of human breast epithelial cells and
immunoprecipitation with the 2,5P antibody, we detected the
appearance of a ,110 kDa P-CTD cleavage fragment in MCF7
and T47D (BRCA1 +/+) cells (Fig. 6B). To confirm the identity of
this CTD fragment, we used comparative immunoprecipitations
with 2,5P and a second anti-CTD specific antibody 8WG16,
which recognizes both unphosphorylated as well as partially
phosphorylated RNAPII CTDs. These anti-CTD antibodies
detected the 110 kDa CTD fragment in both of the BRCA1 (+/
+) cell lines MCF7 and T47D (Fig. 6B). Interestingly, the P-CTD
fragment can be observed in extracts from unirradiated cells
(Fig. 6B) suggesting that P-CTD cleavage may result from RNAPII
pausing and/or spontaneous damage during ongoing transcrip-
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PLoS ONE | www.plosone.org 8 January 2008 | Issue 1 | e1448Figure 5. BRCA1-DSIF complexes are rapidly degraded. (A) Spt4p physically interacts with BRCA1 in yeast. WT cells bearing the GAL::BRCA1 and
GAL::Spt4-V5-LEU2 expression plasmids were induced for co-expression of BRCA1 and Spt4-V5 (16 hrs). Whole cell lysates (WCL) were prepared in
various concentrations of NP40 and either loaded directly (200 ug/lane) or subjected to co-IP reactions overnight using anti-BRCA1 antibody or
normal mouse IgG. Proteins were separated by SDS-PAGE and subjected to Western blotting using anti-V5 antibody as a probe. Spt4p is detected as a
double band in WCL of WT cells migrating between 14 and 20 kDa. This doublet Spt4p band was also detected endogenously using anti-Spt4p
antibody (sc-26353, Santa Cruz) as a probe (data not shown). The upper Spt4-V5 band was observed to interact maximally with BRCA1 at an NP40
concentration of 0.8%. BRCA1 similarly interacted with endogenous Spt4p when anti-Spt4p antibody (sc-26353, Santa Cruz) was used as the IP
antibody (data not shown). (B) Interaction of BRCA1 with SPT5 is dependent on the BRCA1-BRCT domain in human cells. MCF7 and HCC1937 cells
were either left untreated or exposed to UV (20 J/m
2) for 6hr in the presence of the proteasome inhibitor MG132 (50 uM). WCL were prepared and
subjected to co-IP analysis using normal mouse IgG (NLM), anti-BRCA1 or anti-SPT5 mouse monoclonal antibody as the IP reagent. Western
immunoblot (IB) analysis utilized anti-BRCA1 as a probe. The interaction of SPT5 with BRCA1 is observed in both unirradiated and UV-irradiated MCF7
cells. Interaction between BRCA1, and SPT5 is abolished in HCC1937 cells. At the time of irradiation, cells were treated with the proteasome inhibitor
MG132 (50 uM) to inhibit rapid damage-induced degradation of the BRCA1-SPT5 complex. In the absence of proteasome inhibition, no BRCA1-SPT5
interaction was seen following UV irradiation (data not shown). (C) BRCA1 interacts with SPT5 and RNA polymerase II in human cells. Co-IP reactions
using the indicated monoclonal antibodies and normal (non-immune) mouse IgG (NLM) were separated by SDS-PAGE. Western immunoblot (IB)
analysis utilized, anti-BRCA1, anti-2,5P and anti-SPT5 as probes. Both BRCA1 and SPT5 interacted with the full-length hyperphosphorylated form of
RNA polymerase II (IIo). SPT5 interaction with BRCA1 could be detected using either anti-BRCA1 or anti-SPT5 monoclonal antibodies as the
immunoprecipitation reagent. Interaction between SPT5 and BRCA1 was abolished in HCC1937 cells that express a BRCT defective form of BRCA1. (D)
Rapid MMS-induced degradation of BRCA1, SPT5 and RNAPII is BRCT domain dependent. MCF and HCC1937 cells were either left unexposed or
exposed to the radiomimetic methyl methanesulfonate (MMS) for 2 hours at 37uC. Separated proteins were Western immunoblotted using anti-
BRCA1, anti-SPT5, anti-RNAPII antibody N20 and anti-actin as probes. Whereas MMS treatment of MCF7 cells (BRCA1+/+) led to a dramatic
degradation of BRCA1, SPT5 and RNAPII (Rpb1 subunit). MMS treatment of HCC1937 cells (BRCA12/2) resulted in reduced and/or delayed
degradation of the three proteins. These results suggest that the co-degradation may be a BRCT domain dependent process.
doi:10.1371/journal.pone.0001448.g005
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PLoS ONE | www.plosone.org 9 January 2008 | Issue 1 | e1448Figure 6. DNA damage induces RNAPII P-CTD cleavage in yeast and human cells. (A) UV damage in yeast induces RNAPII P-CTD cleavage.
Stationary phase WT diploid yeast cells were irradiated with 120 J/m
2 of UV-irradiation. UV induced a transient 50 kDa RNAPII P-CTD cleavage
fragment at 4–5 hours following irradiation and outgrowth in fresh YPD medium. This fragment was similar in size to that observed following BRCA1
expression. The survival fraction for colony forming ability following UV irradiation was 0.70. P-CTD cleavage was not observed in unirradiated control
cells (data not shown). (B) Antibodies specific for the RNAPII CTD immunoprecipitate a RNAPII P-CTD fragment following UV irradiation. WCL were
prepared from unirradiated and UV-irradiated (20 J/m
2) MCF7 and T47D cells 4 hours after irradiation in the presence of MG132 and subsequently
immunoprecipitated with either 2,5P or 8WG16 anti-CTD antibodies. 8WG16 is specific for unphosphorylated and partially phosphorylated forms of
Rpb1. Immunoprecipitates were separated on polyacrylamide gels and the P-CTD detected by Western blot using the 2,5P anti-CTD antibody as
described above. UV damage enhanced the ability to detect the P-CTD fragment by immunoblotting following immunoprecipitation (IP) with either
2,5P or 8WG16 antibody. Although P-CTD fragment was detected in extracts from unirradiated cells, the ability to IP the P-CTD fragment was
enhanced in extracts from UV-irradiated cells. Images depict proteins greater than 75 kDa. Cross-reacting heavy chain antibodies used in the IP
reactions were detected at ,50 kDa (data not shown). (C) UV-irradiation induces RNAPII P-CTD cleavage in human cells. Human cell lines MCF7 and
HCC1937 were grown to 70–80% confluence and either left unirradiated or irradiated with UV (20 J/m
2). Unirradiated (2) and UV-irradiated (+) cells
were subsequently incubated at 37uC in growth medium with (+) or without (2) the proteasome inhibitor MG132 for 6 hours. Whole cell lysates were
prepared by scraping cells into 95% ethanol at 4uC. Proteins extracted in the ethanol soluble fraction were separated on a 4–15% polyacrylamide gel
and probed with anti-2,5P antibody. Following initial immunoblotting, the membrane was stripped and re-probed with anti-actin antibody to serve
as a loading control. Since the CTD of human RNAPII contains 52 heptapeptide repeat units, UV-induced the cleavage of Rpb1 releasing a P-CTD
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required to detect increased levels of the UV-induced P-CTD
fragment in MCF7 cells (Fig. 6B), this suggests that the P-CTD
fragment is targeted by ubiquitination for rapid proteasome
degradation following cleavage. Persistence of the P-CTD
fragment was also enhanced in MG132 treated yeast cells
expressing BRCA1 (Fig. 4F). These results suggest that damage-
induced P-CTD cleavage is a conserved eukaryotic response.
Damage-induced P-CTD cleavage is a BRCA1-
dependent response
To determine if P-CTD cleavage was a BRCA1-dependent damage
response, we UV-irradiated BRCA1 (+/+)a n dB R C A 1( 2/2)
breast epithelial cells with and without exposure to the proteasome
inhibitor MG132 (Fig. 6C). RNAPII P-CTD cleavage was observed
in UV-irradiated BRCA1 (+/+) cells (MCF7) but not in BRCA1
(2/2) breast cancer cells (HCC1937) following proteasome
inhibition (Fig. 6C). Since treatment with MG132 was required to
visualize the UV-induced P-CTD fragment in BRCA1 (+/+)c e l l s ,
the P-CTD is likely eliminated rapidly via the proteasome pathway.
To confirm that UV-induced P-CTD cleavage was a BRCA1-
dependent process, we ectopically expressed either full-length (wild
type) or an internal deletion (DM) BRCA1 construct in the BRCA1
mutant cell line HCC1937. Following UV-irradiation and protea-
some inhibition with MG132, the P-CTD fragment was only
detectedincellsexpressingthefull-lengthwildtypeBRCA1(Fig.6D).
Expression ofthetruncatedBRCA1 construct(DM)containing anin
frame internal deletion spanning amino acids 775 to 1203 [26] in
HCC1937 cells did not support P-CTD cleavage following UV-
irradiation and proteasome inhibition (Fig. 6D). Furthermore, using
the N20 antibody that recognizes the N terminus of RPB1, we
clearly visualized the reciprocal ,180 kDa RPB1 IIb cleavage
product (a fragment that cannot be detected with the anti-2,5P
antibody) that arises following loss of the P-CTD after DNA damage
in HCC1937 cells that express wild type BRCA1 (Figure S2). Taken
together, these results demonstrate that UV-induced P-CTD
cleavage is mechanistically linked to expression of the wild type
BRCA1 protein in human breast epithelial cells.
DISCUSSION
In trying to define a fundamental role for BRCA1 in breast cancer,
wetookadvantageof theevolutionarydistance between humans and
yeast to identify proteins and/or processes that have the ability to
interact functionally with BRCA1 inyeast; these BRCA1-interacting
partners were identified by finding yeast deletions that suppress
BRCA1-induced lethality. For such ‘‘targets’’ to be biologically
relevant,theyeastgenesandhumanorthologswouldmostlikelyplay
roles in DNA damage responses and genome stability, and they
would have an increased likelihood to physically interact with the
BRCA1 protein. We present evidence that fulfills these criteria for
proteins in the DSIF complex (SPT4/SPT5). Further, DSIF and
other conserved suppressors of BRCA1-induced lethality may be
grouped into a temporally linked mRNA signaling/decay pathway
that responds to DNA damage encountered by RNAPII in actively
transcribing genes at the elongation stage of transcription (Fig. 6E).
Specifically, we identified BRCA1 suppressors that participate in
mRNA transcription elongation as well as mRNA export and decay.
Some of the suppressors (CCR4 and DHH1) were first identified and
characterized as IR resistance genes in a RAD9-dependent,
checkpoint pathway required for G1/S transition following DNA
damage [12]. This checkpoint role for CCR4 and DHH1 has been
subsequentlyconfirmed byotherlaboratories [28] [29] [30][31] and
a role for BRCA1 in G1/S checkpoint arrest following IR damage
has been previously described [32]. Similarly, following overexpres-
sion of BRCA1 in human cells, a G1 arrest was observed [26].
The two yeast genes whose deletion most potently suppressed
BRCA1-induced G1 arrest and lethality were those of the
conserved transcription elongation factor Spt4p and the elonga-
tion phase-specific CTD kinase I (Ctk1-kinase), underlying the
critical role that transcription elongation and RNAPII CTD
phosphorylation play in BRCA1-mediated lethality. Furthermore,
in agreement with previously described physical interactions
observed between BRCA1 and human RNAPII [33] [34],
BRCA1 was found to interact with the P-CTD of RNAPII in
yeast resulting in P-CTD cleavage. It should be noted that the
ethanol procedure used to prevent BRCA1 degradation extracts a
relatively small fraction of the total cellular protein. Therefore, the
amount of RNAPII that undergoes cleavage is unclear at this time.
Disease-associated mutations in BRCA1 that are expressed in
this system neither reduce the viability of the yeast nor result in P-
CTD cleavage suggesting that these events may be causally linked.
Further support for the association of P-CTD cleavage and
lethality comes from the rescue of both phenotypes in the def1D
strain, previously shown to be defective for ubiquitin-mediated
RNAPII degradation following DNA damage [13]. These results
r
fragment that was approximately twice the size (,110 kDa) of the yeast P-CTD fragment which contains 25 heptapeptide repeats (,50 kDa, see
panel A). In repeated experiments, the P-CTD fragment was frequently observed in extracts from unirradiated MG132 treated cells (data not shown)
however, detection of the P-CTD fragment was enhanced in extracts from similarly treated cells exposed to UV. Greatly reduced levels of P-CTD
cleavage was also observed in the BRCA1 defective cell line MDA-MD-436 [57] following UV-irradiation and proteasome inhibition (data not shown).
(D) UV-induced RNAPII P-CTD cleavage is BRCA1-dependent. Cells with a BRCA1-BRCT domain defect (HCC1937) were separately transfected with
empty vector (PC) or vectors expressing truncated BRCA1 (BRCA1-DM) and full-length wild type BRCA1. At 48 hours post transfection cells were UV-
irradiated, treated with MG132 and homogenized in ethanol as described above (panel C) and methods. Aliquots (10 ul) from the insoluble fraction
resuspended in loading buffer were separated by SDS-PAGE and immunoblotted (IB) with the indicated antibodies as described above (panel C). The
P-CTD cleavage fragment was only observed following ectopic expression of full-length wild type BRCA1. The faster mobility of the BRCA1 protein
expressed from the BRCA1-DM construct is due to an in frame internal deletion of 518 amino acids which retains the RING and BRCT domains of
BRCA1 [26]. BRCA1 expressed endogenously in the HCC1937 cells is detected as a lighter band with mobility similar to that of the ectopically
overexpressed BRCA1. (E) A model for BRCA1 DNA damage surveillance during transcription. This model describes a BRCA1-dependent transcription-
mediated checkpoint/surveillance system that is highly conserved among eukaryotes. The components of this pathway were identified as
suppressors of BRCA1-induced lethality in yeast. Following DNA damage within actively transcribing genes, the elongating phosphorylated RNA pol II
(form IIo) is stalled by DNA damage. In yeast, the Ctk1p kinase specifies the phosphorylation pattern of the CTD ‘‘recognized’’ by BRCA1. BRCA1 in the
presence of specific co-factors including DSIF (Spt4p/Spt5p) and the yeast degradation factor Def1p is proposed to bind the P-CTD. This activates a
protease activity that cleaves the CTD from the catalytic domain of Rpb1p (resulting in CTD-less form IIb). We propose this event is an upsteam signal
that activates checkpoint arrest in G1. The checkpoint arrest signal remains ‘‘on’’ until prematurely terminated mRNA is exported from the nucleus
utilizing Mlp1p, Mlp2p and numerous nuclear pore components to be degraded at the cytoplasmic processing body utilizing Ccr4p and Dhh1p.
Following P-CTD cleavage, Rpb1p is targeted for ubiquitin-mediated degradation at the proteasome.
doi:10.1371/journal.pone.0001448.g006
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elongating RNAPII via cleavage of the P-CTD. The highly
conserved nature of the Rpb1p CTD suggested that similar
interactions occur in human cells. Our results in human breast
cancer cell lines fully support this interpretation. We have shown
that P-CTD fragments exist in breast cancer cell lines, are
stabilized by proteasome inhibition, and depend upon the
presence of wild type BRCA1. Reconstitution of the damage-
induced P-CTD accumulation following ectopic expression of wild
type BRCA1 in the mutant HCC1937 cell line provides direct
evidence for this process.
Results from ectopic expression in yeast of mutant BRCA1
proteins and from examination of human HCC1937 cells
(expressing a carboxy terminal BRCA1 deletion) both point to
the BRCT domain of BRCA1 as the mediator of P-CTD cleavage
and associated lethality in yeast. Although the BRCA1-BRCT
domain is necessary to promote P-CTD cleavage, it is not
sufficient. For example, the BRCA1(DM) construct (that contains
intact RING and BRCT domains) fails to reconstitute BRCA1-
induced P-CTD cleavage following DNA damage. Furthermore,
the BRCA1-DM construct can promote ubiquitination of intact
RPB1 [26], suggesting that P-CTD cleavage and ubiquitination
are separate processes. Moreover, the relative ease in transiently
overexpressing the BRCA1-DM construct [26] compared to the
wild type may be related to this defect in P-CTD cleavage.
A critical role for BRCA1 and its stochiometric binding partner
BARD1 in ubiquitin-mediated degradation of phosphorylated
RNAPII has been previously described in vitro [26] [27]. Deletion
of DEF1 inhibits BRCA1-mediated RNAPII CTD cleavage and
degradation much in the same manner as ubiquitin targeted
RNAPII degradation is inhibited following UV in def1D yeast [13].
This suggests that BRCA1 subverts a conserved RNAPII degrada-
tion response to DNA damage to induce lethality in yeast. Following
DNA damage, Def1p may be essential to couple arrested RNAPII to
the proteasome to facilitate its degradation [35].
BRCA1 associates preferentially with the hyperphosphorylated
form of RNAPII [36] [27] [26] and appears to modulate RNAPII
CTD phosphorylation levels [21]. Our finding that loss of the
CTD specific kinase gene CTK1 completely suppresses BRCA1-
induced lethality indicates that BRCA1 interacts preferentially
with the phosphorylated elongating form of the RNAPII specified
by CTDK-I (i.e. phosphorylated on Ser2 and Ser5). The
preferential interaction of BRCT domains with phosphoserine
[37] suggests a potential physical interaction between BRCA1 and
the P-CTD and predicts a critical role for the conserved human
Ctk1p ortholog CRKRS (see CTK1 in Table S1). Others have
reported that, upon treatment with DNA damaging agents, the
association of BRCA1 with RNAPII was disrupted suggesting a
link between DNA damage signaling/repair and transcription
[36]. The apparent damage-induced disruption of BRCA1
interaction with RNAPII may reflect degradation of RNAPII
following DNA damage, dependent on specific co-factors such as
DSIF as suggested in this study. The finding of enhanced
phosphorylation and subsequent proteasome-mediated degrada-
tion of RNAPII that involves P-CTD cleavage following DNA
damage in both yeast ([38] [39] (this study) and human cells [26]
[27] (this study) further illustrates the important conserved role
these ubiquitin-mediated degradation processes play in the
BRCA1 damage response. Moreover, the finding that proteasome
mediated degradation of BRCA1 occurs primarily in G1 [40]
supports a spontaneous role for BRCA1 in degrading RNAPII in
the absence of damage. Alternatively, spontaneous damage within
transcriptionally active genes may account for the P-CTD
cleavage observed in unirradiated breast epithelial cells (Fig. 6B).
Interaction of BRCA1 with the negative elongation factor
NELF-B/COBRA1 [41] combined with the finding that CO-
BRA1, which, as part of the NELF complex interacts with DSIF to
negatively regulate RNAPII transcription [42] is fully supportive of
our determination that the DSIF complex also interacts genetically
and physically with BRCA1 and suggests a damage signaling role
for both COBRA1 and DSIF in concert with BRCA1 and
RNAPII. Our study supports (Fig. 6E) an emerging model that
human cells employ the RNAPII holoenzyme complex during
transcription elongation for DNA damage surveillance [43] [44] .
In this respect, BRCA1 may act as a sensor of DNA damage to
monitor stalling of the transcription apparatus at DNA lesions and,
therefore, participates in a transcriptional checkpoint to signal the
presence of lesions within actively transcribing genes [45]. As
suggested by this study, a G1 checkpoint arrest signal might be
maintained until subsequent transport of the prematurely
terminated transcript for degradation at P-bodies and disassembly
of the RNAPII-BRCA1-DSIF complex by ubiquitin-mediated
degradation at the proteasome (Fig. 6E). Our finding that the
human ortholog of Dhh1p (DDX6) interacts with BRCA1 in the
cytoplasm at P-bodies following DNA damage also supports such a
model (T. Westmoreland and J. Marks, unpublished). The
determination that Dhh1p (and its human ortholog, DDX6) is
an essential component of processing bodies that are sites of
mRNA decay [46] [47] allows us to functionally link transcription
elongation arrest by DNA damage to mRNA export and decay
through BRCA1 and P-CTD cleavage (Fig. 6E). Thus BRCA1
may facilitate repair of DNA damage by mediating P-CTD
cleavage and subsequent degradation of stalled transcription
complexes to allow enhanced access of repair complexes to the
lesion site. This model also accommodates reports that BRCA1
participates in transcription-coupled repair [48] [49] and is
supported by the finding that overexpression of hTREX84 and
dysregulation of mRNA export may be a hallmark of breast
tumors [50]. Taken together our data support BRCA1 playing a
critical role in a novel checkpoint pathway that senses DNA
damage within actively transcribed DNA to initiate cleavage and
degradation of stalled RNAPII elongation complexes. Further-
more, our results showing BRCA1-BRCT function is required for
the rapid alkylation-induced degradation of BRCA1-SPT5 and
RNAPII suggests that chemotherapeutic treatments utilizing
alkylating agents may be clinically effective for treating breast
cancers in which BRCA1-mediated degradation is defective.
Moreover, the use of proteasome inhibitors in concert with
alkylating agents may be equally effective for treating those breast
cancers in which the damage-induced BRCA1-SPT5-RNAPII
degradation pathway remains intact. Defects in this conserved
BRCA1-dependent RNAPII cleavage and degradation pathway
may be critical for the initiation of breast or ovarian cancer,
predicting that genetic defects in other conserved components of
this pathway may also contribute to these diseases.
MATERIALS AND METHODS
Strain and plasmid constructs
Unless otherwise stated, WT and deletion strains are in the diploid
BY4743 strain background. The strains, primers and technique
utilized for deletion strain construction have been described (www-
sequence.stanford.edu/group/yeast_deletion_project/deletions3.
html). The YPH656 YAC containing strain has been previously
described [51]. SPT4 was deleted in the YPH656 strain by PCR
amplifying the spt4D::KanMX loci from the spt4D strain in the
BY4743 strain background obtained from the diploid deletion
strain collection (Open Biosystems, Huntsville, AL) using forward
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reverse (59 GCC TTA GTT GAA TTA CTG GAC GGT AG-39)
primers that flank the spt4D::KanMX deletion sites. Further details
of strain and plasmid constructions are in the supplementary
Methods S1.
Genome-wide screen for suppressors of BRCA1-
induced lethality
Apoolof4746nonessentialdiploiddeletionstrainseachcontaininga
unique 20 base pair genetic tag was obtained from Invitrogen
(Carlsbad, CA). Yeast deletion strains were thawed from a frozen
aliquot of the pooled strains (200 ml, at room temperature) and
grown by inoculating the thawed cells into a 50 ml volume of YPD
liquid medium maintained at 30uC with shaking until a cell count of
1-2610
7 cells/ml was obtained. Cells were made competent and
transformed with 1-2 mg of the previously described [8] selectable
(URA3)h i g hc o p yGAL::BRCA1 YEp24 yeast BRCA1 expression
plasmid (BRCA1 plasmid). Following transformation, cells were
plated directly to synthetic complete (SC) galactose containing
medium (2%) lacking uracil (GAL). Rapidly growing colonies were
picked following 2–4 days incubation at 30uC. Individual colonies
were streak purified on GAL plates. Individual colonies were tested
for the ability to suppress BRCA1-induced lethality by growing WT
and mutant strains containing the BRCA1 plasmid in liquid SC
glucose containing medium (2%) lacking uracil (GLU) until
stationary phase was reached in 96 well dishes. Stationary phase
cultures were serially diluted (5 fold) in sterile water and 2 ml aliquots
were replica plated to GLU and GAL solid medium. Isolates that
showed enhanced survival on GAL plates when compared to WT
were processed for identification [52]. To confirm that the identified
deletions were true suppressors of BRCA1-induced lethality, we
reestablished the BRCA1 plasmid into the individual deletion strains
from the arrayed diploid deletion straincollection (Open Biosystems)
and confirmed enhanced survival on GAL vs GLU.
Suppression of BRCA1-induced G1 arrest and
lethality
To examine suppression of the BRCA1-induced checkpoint delay
at G1, WT, spt4D, def1D and ctk1D strains containing the BRCA1
plasmid were grown to logarithmic phase (1-2610
7 cells/ml) in
liquid GLU medium. Single unbudded (G1) cells were microma-
nipulated into a 465 grid pattern of cells onto solid GLU and
GAL plates using a Singer MSM 300 dissecting microscope
(Singer Instrument Co., Somerset, UK) and photographed hourly.
Western analysis of BRCA1 and RNAPII extracted
from yeast or breast epithelial cells
To minimize degradation of BRCA1 and RNAPII during
extraction from yeast, cell pellets from 50 ml of growth cultures
were homogenized by bead beating in 0.7 ml of 95% ice cold
ethanol on dry ice as previously described [53] with the following
modifications. Cells were lysed by bead beating for 45 second
pulses (66) at maximum velocity in a Fastprep FP120 bead beater
(Q-biogene, Irvine, CA). Lysates were allowed to cool at 4uC for
5 minutes between pulses. Insoluble material was pelleted and the
resulting supernatant transferred to a new microfuge tube and
evaporated to dryness under low heat in a rotary evaporator.
Dried protein samples were resuspended in 26 SDS-PAGE
loading buffer without tracking dye. Protein concentrations were
determined using the NanoOrange detection kit (Invitrogen)
before addition of tracking dye and separation by SDS-PAGE.
Separated proteins were electroblotted to nitrocellulose and
probed with antibodies against the hyperphosphorylated CTD of
RNAPII largest subunit [‘‘anti-2,5P’’: is from a rabbit antiserum
that was raised against a CTD fusion protein exhaustively
phosphorylated by CTDK-I; IgGs were affinity purified (see
[53]), first using the phosphorylated fusion protein and next using
a synthetic CTD 3-repeat peptide phosphorylated on every Ser2
and Ser5 of the heptapeptide repeats (Ser2,5P; see [25])]. Anti-
Act1p (sc-1615, Santa Cruz, Santa Cruz, CA) or anti-Pgk1p (anti-
PGK 22C5, Invitrogen) were used as loading control probes.
Following detection of RNAPII, blots were stripped and reprobed
for BRCA1 (MS110, EMD Chemicals, San Diego, CA).
For mammalian cells, RNAPII was extracted by scraping cells
directly into ice cold 95% ethanol (0.5 ml per 5610
6 cells). Cells
were freeze-thawed three times and insoluble material was pelleted.
The supernatant fluid was evaporated to dryness in a rotary
evaporator and the resulting protein pellet resuspended in 26
loading buffer with b-mercaptoethanol. Alternatively, the pellet of
ethanol insoluble material was resuspended in a large volume of 26
loading buffer (300 ul per 5610
6 cells). Aliquots (10–30 ul) were
separated, electroblotted, and probed as described above.
Exposure of yeast and mammalian cells to DNA
damaging agents
WT and mutant yeast strains were grown to stationary phase at
30u (2 days) in 200 ml of YPD liquid medium in 96 well dishes.
The cells were serially diluted in YPD (5 fold) and replica plated to
YPD plates alone or YPD plates containing 0.02%–0.03% methyl
methanesulfonate (MMS), 200mM hydroxyurea (HU) or 66%
crude zymocin as previously described [12]. Cells plated to YPD
alone were leftunexposed or irradiated with 80 kradsofc-irradiation
at a dose rate of 2.38 krads/min. Cells were continually exposed to
HU, MMS or zymocin, by incubating the plates for 2–3 days at 30u.
c-ray survival curves were generated as previously described [12].
ForUV-irradiation,WTdiploidcellswere grown to stationaryphase
as described above in 80 ml of YPD liquid medium. Unirradiated
cells, (5 ml) were concentrated into a pellet by centrifugation and the
supernatant fluid discarded. The cell pellet was flash frozen and
stored as described above. A 40 ml volume of the remaining cell
suspension was concentrated into a pellet by centrifugation, washed
16insterileH2Oandresuspendedin15 mlofH2O.CellswereUV-
irradiated in a sterile 100 mm Petri dish with constant agitation at a
dose rate of ,1J / m
2/sec to a total dose of 120 J/m
2 using a
germicidal lamp. Following irradiation cells were diluted to 40 ml in
H2O and mixed with 40 ml of 26liquid YPD. Cells were incubated
at 30uC with vigorous agitation and 10 ml aliquots were
concentrated by centrifugation, the supernatant was discarded and
the resulting pellet was flash frozen at hourly intervals. Frozen cell
pellets were extracted on dry ice in 0.4 ml 95% ethanol as described
above. Extracted protein samples were resuspended in 50 ul of 26
loading buffer and 20 ul volumes separated on Tris-HCL gels as
described above. RNAPII CTD cleavage was detected using anti-
2,5P (P-CTD) antibody. Unirradiated and UV-irradiated cells were
diluted in sterile water and plated to YPD plates to determine the
relative survival of colony forming ability following UV-irradiation.
MCF7 and HCC1937 human breast cancer cell lines were
grown to ,80% confluence in RPMI 1640 medium containing
10% fetal bovine serum. Medium was removed from the cell
monolayers and either left unirradiated or UV-irradiated (20 J/
m
2) using a UV Stratalinker 1800 (Stratagene, La Jolla, CA). Cells
were refed with fresh medium with or without MG132 for 4–
6 hours and whole cell lysates (WCL) prepared. For MMS
treatment of human cells, MMS was placed in fresh complete
RPMI medium and cells were incubated for 2 hours at 37uC.
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yeast
WT and spt4D strains containing the BRCA1 plasmid were grown
to stationary phase and total genomic DNA extracted [54]. Equal
aliquots of extracted DNA were separated on a 0.7% agarose gel,
transferred to a nylon membrane by Southern blotting using a
positive pressure apparatus (Stratagene) and immobilized by UV
cross-linking as previously described [54]. The BRCA1 plasmid
was labeled and visualized on the membrane following hybridiza-
tion using the non-radioactive AlkPhos Direct labeling and
detection kit (Amersham Biosciences, Piscataway, NJ).
Proteasome inhibition in yeast and mammalian cells
using MG132
The erg6D strain [55] in the BY4743 background containing the
BRCA1 plasmid was induced for BRCA1 expression in GAL as
described above. At 6 hours following GAL induction, cells were
treated with 50 mM MG132 or vehicle (DMSO). Undamaged MCF7
or HCC1937 cells or those exposed to UV (20 J/m
2)w e r ec o n -
comitantly treated with MG132 (dissolved in DMSO) resuspended in
complete RPMI medium to a final concentration of 50 mM.
Co-immunoprecipitation
To prepare yeast WCL, cells were concentrated by centrifugation
and residual growth medium discarded. Cell pellets were
resuspended in 0.5 ml of ice cold NP40 buffer (0.05–0.1%
NP40, 50 mM Tris pH 8.0, 5 mM EDTA, 150 mM NaCl) plus
protease inhibitors and lysed by bead beating for 45 second pulses
at maximum velocity in a Fastprep FP120 bead beater (Q-biogene,
Irvine, CA). Lysates were allowed to cool at 4uC for 5 minutes
between pulses. WCL were precleared by centrifugation followed
by incubation of the supernatant for 24 hrs at 4uC normal mouse
IgG (Vector Laboratories, Burlingame, CA) plus a 1:1 mixture of
Protein A and G beads (Roche Diagnostics, Nutley, NJ). For co-IP
interactions, precleared lysate was reacted overnight at 4uC with
normal mouse IgG, anti-V5 (Invitrogen) or anti–BRCA1 antibody
(MS110) plus Protein A and/or G agarose. IP reactions were
washed 2-36 in NP40 buffer with protease inhibitors. Following
the last wash, SDS-PAGE loading buffer was added to the beads
and heated at 95uC for 5 minutes prior to SDS-PAGE.
For breast cancer cell lines, culture monolayers were gently
washed 36in ice cold PBS and lysed with gentle shaking at 4uCi n
0.5 ml of NP40 buffer (0.08% NP40) plus protease inhibitors. WCL
were precleared with normal mouse IgG and subjected to co-IP
analysis as described above using anti-RNAPII CTD antibody, anti-
BRCA1 antibody (MS110), or anti-SPT5 antibody (anti-DSIF
61107, BD Biosciences, San Jose, CA). For detection on Western
blots; N20 (sc-899, Santa Cruz) or anti-2,5P were used as probes.
Immunofluorescent detection of BRCA1 in yeast
IF detection of BRCA1 in yeast was adapted from previously
described methods [56]. Briefly, after BRCA1 expression was
induced by shaking for six hours at 30uC in GAL, cells were fixed
in formaldehyde for 1 hr at RT, recovered by centrifugation,
resuspended in 50 mM phosphate-buffered formaldehyde plus
sorbitol (1.2M) and fixed a further two hours at RT. After
Zymolyase treatment (1 mg/ml Zymolyase 100T ICN) for 30 min
at 37uC, cells were washed and stored at 4uC for antibody staining.
For BRCA1 detection, cells were placed onto polylysine-coated
slides. The cells were fixed again at 220uC in methanol and
acetone and then blocked (5% normal goat serum, 1% glycerol,
0.1% BSA, 0.1% fish skin gelatin in sterile PBS) for 30 minutes.
The primary antibody (MS1101 mg/ml) was reacted for 2 hrs at
RT, followed by incubation for 1 hr with a goat anti-mouse IgG
conjugated with Alexflour 488 (Jackson Immunoresearch Labora-
tories, West Grove, PA). Hoechst 33342 diluted 1:10,000 in PBS
was added 5 minutes before coverslipping.
SUPPORTING INFORMATION
Table S1 Identification of yeast diploid deletion strains that
suppress lethality following heterologous expression of the tumor
suppressor BRCA1.
Found at: doi:10.1371/journal.pone.0001448.s001 (0.15 MB
DOC)
Figure S1 Characterization of the BRCA1-induced P-CTD
fragment. The 50 kDa BRCA1-induced fragment detected by anti
2,5P is specific for the RNAPII CTD. The yeast strain CTD-
His10a expresses an Rpb1p allele with an in frame C-terminal
His10 tag fused to the Rpb1p CTD (left panels). The 12AR yeast
strain expresses Rpb1p with a truncated CTD containing 12
heptapeptide repeats. These strains were induced for BRCA1
expression and extracted in ethanol as described above. For the
CTD-His10a strain, Western blots were probed with anti-2,5P P-
CTD antibody (upper panels), stripped and reprobed with anti-His
antibody (Amersham, lower panel). The anti-His antibody detects
the 50 kDa fragment previously detected by the anti-2,5P CTD
antibody. The yeast strain expressing a truncated RNAPII CTD
(12AR) exhibited a smaller P-CTD fragment when compared to
the BRCA1-induced fragment from the WT strain containing the
full-length Rpb1p CTD using the anti-2,5P antibody as a probe.
Lower panel is a longer exposure of the upper panel.
Found at: doi:10.1371/journal.pone.0001448.s002 (7.72 MB TIF)
Figure S2 DNA damage induces BRCA1-dependent cleavage of
RPB1 in breast epithelial cells. Human breast epithelial cells that are
mutant for BRCA1 (HCC1937) were transfected with PC control,
BRCA1-delta M and wild-type BRCA1 as described in methods and
Fig. 6D. Following transfection, cells were UV-irradiated (20 J/m
2)
and treated with the proteasome inhibitor MG132 for 6 hours.
Sample aliquotes (30 ul) identical to that described in Fig. 6D were
separated by SDS-PAGE and transferred to nitrocellulose. The
Western blot was probed with the N20 antibody specific for the N
terminus of RPB1. Following initial immunoblotting (see Fig. 6D),
stripped membranes were reprobed with anti-actin antibody to serve
as a loading control. The majority of full-length RPB1was converted
from the hypophosphorylated from of RPB1 (IIa) to the hyperpho-
sphorylated form of Rpb1 (IIo). UV damage induced a BRCA1-
dependentcleavageofRPB1intotheIIbform(,180 kDa) and the P-
CTD fragment (see Fig. 6D) that is not detected by the N20 antibody.
Found at: doi:10.1371/journal.pone.0001448.s003 (3.75 MB TIF)
Methods S1
Found at: doi:10.1371/journal.pone.0001448.s004 (0.05 MB
DOC)
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